Susquehanna International Group’s Adial Pharmaceuticals Warrant ADILW Stock Holding History

Susquehanna International Group’s Portfolio ADILW Stock Details ADILW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21,686	Closed	-$8K	–	13018
2020 Q4	$8K	Buy	+21,686	New	+$7.29K	﹤0.01%	10922
2019 Q4	–	Sell	-16,505	Closed	-$3K	–	10903
2019 Q3	$3K	Buy	16,505 +490	+3%	+$117	﹤0.01%	10060
2019 Q2	$3K	Buy	16,015 +5,015	+46%	+$1.72K	﹤0.01%	10115
2019 Q1	$4K	Sell	11,000 -7,069	-39%	-$5.17K	﹤0.01%	8680
2018 Q4	$10K	Buy	+18,069	New	+$7.75K	﹤0.01%	8747

Other funds holding ADILW

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Susquehanna International Group's ADILW Position: Q1 2021 in Review

Susquehanna International Group sold out of Adial Pharmaceuticals Warrant (ADILW) in Q1 2021, closing a stake of 21,686 shares — an estimated $8K sold.

Susquehanna International Group first reported a position in ADILW in Q4 2018 and held it in 5 quarters. The position peaked at $10K in Q4 2018. 2 funds tracked by Wall St. Rank hold ADILW as of Q1 2021.

Susquehanna International Group reported no remaining Adial Pharmaceuticals Warrant position as of Q1 2021 after selling out during the quarter.
Susquehanna International Group sold 21,686 Adial Pharmaceuticals Warrant shares in Q1 2021, an estimated $8K.
Susquehanna International Group first reported a position in Adial Pharmaceuticals Warrant in Q4 2018 and held it in 5 quarters.
Susquehanna International Group's Adial Pharmaceuticals Warrant position peaked at $10K in Q4 2018.
2 funds tracked by Wall St. Rank held Adial Pharmaceuticals Warrant as of Q1 2021.

Based on Susquehanna International Group's 13F filing for Q1 2021, filed 17 May 2021.